Skip to main content
. 2015 Mar 12;156(6):2323–2337. doi: 10.1210/en.2014-2006

Table 1.

Circulating Maternal Metabolites (Amino Acids, Acylcarnitines, and FFAs) (Nanomoles per Milliliter) With the Highest Concentrations in Plasma and Those That Differed Significantly Among Treatment Groups

Metabolites C T T-Flutamide T-Rosi CV, % P Adj
Amino acids
    Glycine 461.3 ± 28.6 498.2 ± 78.6 415.9 ± 47.6 453.7 ± 45.2 8.0 NS
    Valine 175.3 ± 14.2 166.9 ± 8.2 187.8 ± 16.4 189.4 ± 11.9 4.5 NS
    Leucine 152.3 ± 9.7 125.5 ± 7.9 151.3 ± 14.4 150.5 ± 12.74 5.7 NS
    Glutamic acid 151.1 ± 10.5 124.9 ± 5.7 166.0 ± 8.9 169.1 ± 18.4 9.1 NS
    Alanine 145.8 ± 21.3 144.3 ± 9.7 137.5 ± 17.4 141.5 ± 19.6 5.4 NS
Acylcarnitines
    L-carnitine 11.559 ± 2.066 14.067 ± 1.655 16.844 ± 4.243 10.763 ± 1.305 8.6 NS
    Decenoyl (C10:1) 1.756 ± 0.311 3.602 ± 0.815 2.267 ± 0.668 2.844 ± 0.630 1.8 NS
    Propionyl-(C3) 0.592 ± 0.025 0.741 ± 0.060 0.595 ± 0.081 0.861 ± 0.104 1.7 NS
    3-Hydroxydodecanoyl- (C12-OH) 0.009 ± 0.001a 0.004 ± 0.001b 0.004 ± 0.001b 0.007 ± 0.001a 9.3 <.01
    3-Hydroxytetradecanoyl- (C14-OH) 0.025 ± 0.005a 0.010 ± 0.001b 0.008 ± 0.001b 0.018 ± 0.002a 5.3 <.05
FFAs
    Stearic acid (18:0) 41.64 ± 4.11 40.99 ± 5.92 37.46 ± 3.52 35.51 ± 2.03 0.11 NS
    Oleic acid (18:1 [n-9]) 31.16 ± 6.28 40.94 ± 4.39 41.70 ± 7.32 32.47 ± 2.36 0.37 NS
    Palmitic acid (16:0) 15.75 ± 1.74 17.88 ± 2.19 19.43 ± 2.55 15.74 ± 1.09 1.09 NS
    Linoleic acid (18:2) 2.69 ± 0.59 4.69 ± 1.09 5.67 ± 0.78 6.07 ± 1.83 0.57 NS
    α-Linolenic acid (18:3 [n-3]) 0.10 ± 0.030a 0.55 ± 0.17a 0.92 ± 0.19b 0.43 ± 0.12a 0.43 <.05

Abbreviations: Adj, adjusted; C, controls; CV, coefficient of variation; NS, not significant; T, treated with T; T-Flutamide, treated with T plus flutamide; T-Rosi, treated with T plus rosiglitazone. Values with different superscript letters (a, b) differ significantly (P < .05). NS values do not differ significantly (P > .05). All P values are shown as an adjusted P value (P adj). For a more complete list, see supplemental Tables 3–5.